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Abstract
Introduction: The most common complication 
of permanent hemodialysis (HD) vascular access 
is thrombosis, with some cases being related to a 
hypercoagulable state. Antiphospholipid antibody 
syndrome (APAS) is a cause of increased thrombotic 
tendency, and this may complicate the management of 
such patients on HD.
Case report: We describe a 48-year-old man with end 
stage renal disease (ESRD) of undetermined cause who 
was referred to our tertiary care center for urgent renal 
transplantation.  He was maintained on regular HD, but 
his dialysis care was complicated by recurrent vascular 
access thrombosis to the extent that no further access site 
was available for his routine renal replacement treatment. 
A thorough thrombophilia screen confirmed the presence 
of antiphospholipid antibodies. A diagnosis of APAS 
was made and he was anticoagulated with warfarin. A 
transhepatic dialysis catheter was inserted and HD was 
resumed, but this was complicated by a large intra-
abdominal hematoma. His anticoagulation was reversed 
and he improved, but his transhepatic catheter got clotted. 
This catheter was removed and a translumbar dialysis 
catheter was inserted as a last resort. Within a week of his 
arrival to our hospital, he recieved a kidney transplant. 
Graft function was delayed, but eventually improved, 
though he has never regained normal renal function.
Conclusion: The presence of APAS can complicate 
HD management by causing recurrent vascular access 
thrombosis and failure, and nephrologists must remain 
alert to this possibility. Anticoagulation management of 
these patients must be handled with extra care to avoid 
bleeding complications.
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Introduction
The most common complication of permanent 
hemodialysis (HD) vascular access is thrombosis, 
accounting for 80 to 85 percent of arteriovenous (AV) 
access loss.  Anatomic problems, mainly venous stenosis, 
are by far the major predisposing factors for thrombosis, 
being responsible for 80 to 85 percent of all cases [1-2]. 
Arterial stenoses and non-anatomic problems such as 
excessive post-dialysis fistula compression, hypotension 
and hypovolemia account for the remaining cases, with 
some cases being related to a hypercoagulable state 
[3-6].
In this case report, we describe a patient with the 
primary antiphospholipid antibody syndrome (APAS) 
complicated by recurrent AV fistulae and vascular access 
thromboses. We outline his management and conclude by 
summarising a guideline-based approach to the care of 
such problematic cases. 
Case report
A 48-year-old man with end stage renal disease (ESRD) of 
undetermined cause was referred to our tertiary care center 
for urgent renal transplantation.  He had a long history of 
hypertension but had no history of diabetes mellitus.  He 
was maintained on regular HD, but his dialysis care was 
complicated by recurrent vascular access thrombosis to 
the extent that no further access site was available for his 
routine renal replacement treatment. 
A thorough thrombophilia screen confirmed the presence 
of antiphospholipid antibodies, while antinuclear 
antibody and anti ds-DNA antibodies were negative. A 
diagnosis of APAS was made and he was anticoagulated 
with warfarin. On the day of arrival to our hospital, a 
transhepatic dialysis catheter was inserted and HD was 
resumed. During the ensuing days, the patient became 
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hypotensive and his hemoglobin dropped markedly. 
Investigations revealed the presence of a large intra-
abdominal hematoma that was related to his transhepatic 
dialysis catheter.  He was resuscitated, his anticoagulation 
was reversed and he improved. Unfortunately, his 
transhepatic catheter got clotted. This was removed and 
a translumbar dialysis catheter was inserted as a last 
resort. 
Renal transplant workup was completed within a week of 
his arrival to our hospital. Soon afterwards, he received 
a cadaveric renal transplant. Graft function was delayed, 
but eventually improved, though he has never regained 
normal renal function.
Discussion
APAS is a disorder characterized by arterial and 
venous thrombotic events associated with the presence 
of the so called antiphospholipid antibodies, which 
are auto-antibodies directed against phospholipids or 
phospholipids binding proteins. APAS can either be 
primary or secondary; in the latter case it is associated 
with other autoimmune diseases, particularly systemic 
lupus erythematosus (SLE), or related to acute infections 
or certain drug exposures. Four types of antiphospholipid 
antibodies have been characterized: anticardiolipin 
antibodies, antiprothrombin antibodies, anti-ethanolamine 
antibodies and anti-beta2-glycoprotein I antibodies.  It 
is not clear whether the presence of antiphospholipid 
antibodies is involved in the pathogenesis of APAS or 
is an epiphenomenon. However, the presence of these 
antibodies is strongly associated with lupus anti-coagulant 
activity of serum and to the risk of arterial and venous 
thrombosis, spontaneous abortion and thrombocytopenia 
[7]. 
According to the Sapporo criteria for the diagnosis of the 
APAS, which are adopted by the American College of 
Rheumatology, the isolated detection of antiphospholipid 
antibodies in a patient’s serum is not enough to make the 
diagnosis of APAS [8]. For a diagnosis of APAS to be 
made, the patient must have at least one clinical criterion 
and one laboratory criterion for APAS. Clinical criteria 
include one or more confirmed episodes of vascular 
thrombosis, or three un-explained consecutive abortions, 
or an un-explained late pregnancy loss, or a premature 
birth due to pre-eclampsia or placental insufficiency. 
Laboratory criteria include the detection of anicardiolipin 
antibodies in high titer or lupus anticoagulant activity in 
the patient’s serum on at least two occasions, six weeks 
apart [8].
Renal complications occur in as many as 25% of patients 
with the APAS [9].  For the most part, these complications 
are directly related to thrombotic occlusions of glomerular 
capillaries; however, they occasionally involve the renal 
veins and renal arteries. Clinical manifestations include 
acute and subacute renal failure, active urinary sediment, 
the nephrotic syndrome and hypertension [9, 10]. 
Pathological entities include thrombotic microangiopathy, 
focal segmental glomerulosclerosis, ischemic interstitial 
nephritis with fibrosis and renal infarction [9, 10]. In 
addition, the presence of antiphospholipid antibodies in 
patients with ESRD often complicates their management. 
The presence of the antiphospholipid antibodies doubles 
the frequency of thrombotic occlusion of vascular access 
sites in HD patients [4].
The development of these antibodies may be related to 
the type of HD access used, since they are more frequent 
in patients with AV grafts compared to patients with AV 
fistulae. In a cross-sectional study that evaluated HD 
patients at a single dialysis facility, 22% of patients with 
AV grafts had a raised titer of anticardiolipin antibodies, 
while only 6% of patients with AV fistulae had similarly 
raised titers [5]. However, another likely explanation for 
the higher incidence of antiphospholipid antibodies in 
patients with AV grafts is that patients who already have 
the antiphospholipid antibodies are more likely to suffer 
from repeated vascular access failure and are more likely 
to require the placement of a synthetic AV graft. The 
development of antiphospholipid antibodies may also 
be related to the type of dialysis membrane used, with a 
greater incidence being associated with  frequent use of 
cuprophane membranes (68% versus 34%, P<0.05) [6].
Vascular thrombosis is usually recurrent in APAS and all 
patients who have major or recurrent thrombotic event 
should receive life-long warfarin therapy with a target 
INR of 3.0 or higher [11, 12]. In a retrospective study 
of 147 patients with the APAS, recurrent thrombosis 
affected 30% of patients per year in those who did not 
receive long-term anticoagulation therapy. Aspirin alone 
was of no benefit, while low intensity warfarin (INR<3) 
with or without low dose aspirin offered only modest 
protection against recurrent thrombosis (23% of patients 
per year). High intensity dose warfarin (INR>3) with or 
without low dose aspirin markedly reduced the incidence 
of recurrent thrombosis (1.3% of patients per year) 
[11]. Treatment with warfarin may also be successful in 
increasing AV graft survival in HD patients with elevated 
anticardiolipin levels and a history of vascular access 
failure [11, 12]. 
The thrombophilic potential of these antibodies extends 
to the post-renal transplant stage as well, leading to a 
much higher early as well as late renal allograft loss in 
those who are not properly anticoagulated [13, 14]. In 
a study of 11 renal transplant recipients with APAS, all 
seven patients who did not receive anticoagulants lost 
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HD access failure
their allografts due to renal thrombosis within one week 
of surgery, while three of the four patients who received 
anticoagulation had functioning grafts for over two years 
post transplantation. However, among another group of 37 
patients who had high titers of anticardiolipin antibodies 
without previous history of thrombosis, no allograft was 
lost to renal thrombosis [13].
In another study, nine patients with APAS received 
cadaveric kidney transplants, seven of whom were 
treated with warfarin and the remaining two were 
treated with heparin. Of the seven patients treated with 
warfarin, five did not have thrombotic complications 
post-transplant. However, three of these patients were 
taken off warfarin due to bleeding complications 6-12 
months post-transplant; they all returned to dialysis 
shortly thereafter. The remaining two patients have 
maintained their allograft on warfarin therapy for three 
and five years post-transplant. The other two patients 
had post-transplant renal thrombosis within 24 hours of 
their transplantation despite warfarin therapy. Of the two 
patients treated with heparin, one was doing well at 6 
years post-transplant while the other had early allograft 
loss due to thrombosis [14].
Recommendations for managing antiphospholipid 
antibody-positive patients on HD, peri-operatively and 
post-transplantation are [15]:
•   If warfarin is used preoperatively, it must be stopped a 
few days prior to surgery. 
• For general surgery prophylaxis, 5000 units of 
unfractionated heparin or 30 mg of enoxaparin is given 
subcutaneously one or two hours preoperatively. 
• If there are no immediate postoperative bleeding 
complications, warfarin can be resumed the evening after 
surgery. Prophylactic heparin is continued until the INR 
is in therapeutic range.
A possible future role for the use of hydroxychloroquine 
in the management of APAS in renal patients is suggested 
by its efficacy in reducing thrombotic tendency in 
experimental animal studies [16].
Conclusion
Nephrologists must remain alert to the possibility of 
APAS being the cause of repeated vascular access 
thrombosis and failure in HD patients. Anticoagulation 
management of these patients must be handled with extra 
care to avoid bleeding complications.
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